Dyne Therapeutics (NASDAQ:DYN) Trading Down 7.1% - Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) shares dropped 7.1% during mid-day trading on Friday . The company traded as low as $27.80 and last traded at $28.16. Approximately 245,371 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 1,489,411 shares. The stock had previously closed at $30.31.

Wall Street Analysts Forecast Growth

DYN has been the subject of a number of research reports. Piper Sandler reaffirmed an "overweight" rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research note on Monday, September 23rd. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday. Guggenheim boosted their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Thursday, August 15th. StockNews.com cut Dyne Therapeutics from a "hold" rating to a "sell" rating in a report on Monday, September 16th. Finally, Stifel Nicolaus lifted their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a "buy" rating in a research note on Friday, August 16th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $51.40.

Dyne Therapeutics Price Performance

The firm has a market cap of $2.89 billion, a PE ratio of -7.97 and a beta of 1.10. The firm has a 50-day simple moving average of $32.48 and a 200 day simple moving average of $35.17.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). Sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.02 earnings per share for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox acquired 32,000 shares of the company's stock in a transaction that occurred on Wednesday, September 4th. The shares were bought at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the transaction, the chief executive officer now directly owns 8,000 shares of the company's stock, valued at approximately $264,320. This represents a -133.33 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dirk Kersten sold 79,411 shares of the firm's stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the sale, the director now directly owns 234,127 shares in the company, valued at approximately $8,533,929.15. The trade was a 25.33 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 158,975 shares of company stock worth $5,693,789. Corporate insiders own 20.77% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. purchased a new stake in Dyne Therapeutics in the first quarter worth about $140,666,000. FMR LLC raised its stake in Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company's stock worth $324,239,000 after acquiring an additional 3,707,734 shares during the period. Janus Henderson Group PLC lifted its holdings in Dyne Therapeutics by 23,512.0% during the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company's stock valued at $75,915,000 after purchasing an additional 2,663,910 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Dyne Therapeutics by 8,284.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company's stock worth $32,141,000 after purchasing an additional 1,118,590 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Dyne Therapeutics by 47.7% in the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company's stock worth $97,669,000 after purchasing an additional 1,110,629 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.